Jana Van De Goor

Dr. van de Goor has over 15 years of research & development experience with industry leader Genentech. Most recently, she led global project teams from pre-clinical phase through the launch including CMC leadership for 2nd generation Rituxan and the global development team for Trastuzumab emtansine, a first in class antibody-drug conjugate for the treatment of Her-2 positive metastatic breast cancer (approved in 2013). In her early years at Genentech, she led research to understand the molecular mechanism of cell death of large-scale production cultures and collaborated with V. Dixit to develop novel cell lines expressing apoptosis inhibitors to prolong cell viability.

Prior to joining, Genentech she was a postdoctoral fellow at the University of California, San Francisco investigating the mechanism of synaptic transmission in D. melanogaster. Jana earned her Ph.D. in Molecular Biology from the University of Technology in the Netherlands.